An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France
- 1 February 2003
- journal article
- clinical trial
- Published by Elsevier in Diabetes & Metabolism
- Vol. 29 (1), 29-35
- https://doi.org/10.1016/s1262-3636(07)70004-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- A regression-based method for estimating mean treatment cost in the presence of right-censoringBiostatistics, 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyThe Lancet, 2000
- Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal functionJournal of Human Hypertension, 1999
- Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathyDiabetes, 1997
- Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathyKidney International, 1996
- Five‐Hundred Life‐Saving Interventions and Their Cost‐EffectivenessRisk Analysis, 1995
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993